Effect of Mahanimba in Tamaka-shwasa(Bronchial Asthma)

Pharmacognostical and Exploratory Study of Mahanimba Melia azedarach Linn Leaves and Stem Bark on Tamaka Shwasa Bronchial Asthma - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070153

Enrollment

Registered

2024-07-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J452- Mild intermittent asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between the age group of 18 to 40 years of either sex present with clinical features of Tamaka Shwasa. 2. Mild persistent cases of Asthma of duration more than 6 months (as per WHO GINA guideline) 3. Recurrent episodes of Wheezing, Breathlessness, and Coughing particularly at night or in the morning.

Exclusion criteria

Exclusion criteria: 1. Patients below 18 years and above 40 years. 2. Tuberculosis (Pulmonary). 3. Chronic obstructive pulmonary disease(COPD). 4. Pleural effusion & Emphysema. 5. Patient who need Salbutamol inhaler daily. 6. HIV positive cases. 7. Patients suffering from systemic disorders like renal failure, hypertension, Diabetes Mellitus etc. 8. Pregnancy and lactating mother.

Design outcomes

Primary

Measure	Time frame
changes in 1. complete blood count 2. Radiological test - chest X-ray 3. Pulmonary function test- SpirometryTimepoint: 45days	—

Secondary

Measure	Time frame
Pharmacognostical and Phytochemical analysis of Mahanimba (Melia azedarach.Linn) to determine the family character and different constituents of plants.Timepoint: 45days	—

Countries

India

Contacts

Public ContactDr Chandan Singh

Post Graduate Institute Of Ayurveda, DSRRAU, Jodhpur

deveshpareek63397@gmail.com7073063955

Outcome results